NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use

INTRODUCTION: Intranasal (IN) naloxone is widely used to treat opioid overdoses. The advantage of nasal administration compared with injection lies in its suitability for administration by lay people as it is needless. Approved formulations of nasal naloxone with bioavailability of approximately 50%...

Descripción completa

Detalles Bibliográficos
Autores principales: Skulberg, Arne Kristian, Tylleskär, Ida, Braarud, Anne-Cathrine, Dale, Jostein, Heyerdahl, Fridtjof, Mellesmo, Sindre, Valberg, Morten, Dale, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Emergency Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662429/
https://www.ncbi.nlm.nih.gov/pubmed/33184084
http://dx.doi.org/10.1136/bmjopen-2020-041556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662429/
https://www.ncbi.nlm.nih.gov/pubmed/33184084
http://dx.doi.org/10.1136/bmjopen-2020-041556

Ejemplares similares